Nuvectis Pharma, Inc. Quarterly Debt-to-equity in % from Q3 2022 to Q3 2024

Taxonomy & unit: ratio: %
Description: Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary: Nuvectis Pharma, Inc. quarterly Debt-to-equity history and growth rate from Q3 2022 to Q3 2024.
Nuvectis Pharma, Inc. Debt-to-equity for the quarter ending September 30, 2024 was 49.8 %, a 55.7% increase year-over-year.

Debt-to-equity, Quarterly (%)

Debt-to-equity, YoY Quarterly Growth (%)

Period	Value	YoY Chg	Change %	Date
Q3 2024	49.8	+17.8	+55.7%	Sep 30, 2024
Q2 2024	43.3	+14.7	+51.5%	Jun 30, 2024
Q1 2024	36.2	+6.42	+21.6%	Mar 31, 2024
Q4 2023	34.3	+7.15	+26.3%	Dec 31, 2023
Q3 2023	32	-3.9	-10.9%	Sep 30, 2023
Q2 2023	28.6			Jun 30, 2023
Q1 2023	29.7			Mar 31, 2023
Q4 2022	27.2			Dec 31, 2022
Q3 2022	35.9			Sep 30, 2022

* An asterisk sign (*) next to the value indicates that the value is likely invalid.